4D Molecular Therapeutics Inc

FDMT

Company Profile

  • Business description

    4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).

  • Contact

    5858 Horton Street
    Suite 455
    EmeryvilleCA94608
    USA

    T: +1 510 505-2680

    E: [email protected]

    https://www.4dmoleculartherapeutics.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    196

Stocks News & Analysis

stocks

ASX gold miner under pressure to sell by activist investor

Activist investor presses gold miner on selling to larger players.
stocks

Ask the Analyst: Will Amcor lose its dividend aristocrat status?

When consistency becomes constraint.
stocks

Chart of the Week: We see opportunity in this beaten down industrial player

The market sees risks and are discounting the shares excessively.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,859.2076.30-0.85%
CAC 408,244.290.000.00%
DAX 4024,944.95149.010.60%
Dow JONES (US)51,561.93874.861.73%
FTSE 10010,360.3228.020.27%
HKSE25,253.40379.81-1.48%
NASDAQ26,830.9623.02-0.09%
Nikkei 22566,292.851,177.84-1.75%
NZX 50 Index13,120.6219.010.15%
S&P 5007,584.3130.630.41%
S&P/ASX 2008,629.5075.60-0.87%
SSE Composite Index4,057.7826.19-0.64%

Market Movers